Siren L.L.C. Cuts Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Siren L.L.C. reduced its stake in NewAmsterdam Pharma by 8.8% in the first quarter, maintaining approximately 2.3% of its portfolio in the company.
• Several large investors, including Wellington Management Group LLP and Aberdeen Group plc, significantly increased their stakes in NewAmsterdam Pharma during the same period.
• Analysts have assigned a consensus rating of "Moderate Buy" for NewAmsterdam Pharma, with an average target price of $41.55, while some firms set price targets as high as $45.00.

Siren L.L.C. lessened its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 8.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,912,030 shares of the company's stock after selling 183,608 shares during the quarter. NewAmsterdam Pharma makes up 2.3% of Siren L.L.C.'s holdings, making the stock its 13th biggest position. Siren L.L.C. owned about 1.74% of NewAmsterdam Pharma worth $39,139,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in NAMS. Barclays PLC boosted its holdings in shares of NewAmsterdam Pharma by 120.0% in the 4th quarter. Barclays PLC now owns 16,713 shares of the company's stock valued at $429,000 after buying an additional 9,117 shares during the last quarter. Tudor Investment Corp ET AL bought a new position in NewAmsterdam Pharma during the 4th quarter worth $1,342,000. The Manufacturers Life Insurance Company bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $221,000. Northern Trust Corp bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $556,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $524,000. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Performance

Shares of NAMS traded up $0.54 on Wednesday, reaching $25.17. The stock had a trading volume of 418,554 shares, compared to its average volume of 868,276. The company has a 50-day simple moving average of $22.54 and a 200-day simple moving average of $20.43. The firm has a market capitalization of $2.83 billion, a price-to-earnings ratio of -15.56 and a beta of -0.01. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. The business had revenue of $19.15 million during the quarter, compared to analysts' expectations of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%. On average, analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 8,269 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $24.86, for a total value of $205,567.34. Following the transaction, the chief accounting officer directly owned 15,000 shares in the company, valued at approximately $372,900. This trade represents a 35.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Douglas F. Kling sold 100,000 shares of the company's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $19.29, for a total value of $1,929,000.00. Following the completion of the sale, the chief operating officer owned 44,000 shares of the company's stock, valued at approximately $848,760. The trade was a 69.44% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have bought 12,835 shares of company stock worth $248,134 and have sold 256,881 shares worth $5,445,954. 20.84% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NAMS. Wells Fargo & Company initiated coverage on shares of NewAmsterdam Pharma in a report on Monday, August 25th. They issued an "overweight" rating and a $45.00 price objective for the company. Cantor Fitzgerald assumed coverage on NewAmsterdam Pharma in a report on Wednesday, June 4th. They set an "overweight" rating and a $42.00 price objective for the company. The Goldman Sachs Group initiated coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They set a "neutral" rating and a $27.00 target price on the stock. Citigroup initiated coverage on NewAmsterdam Pharma in a research report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 price objective on the stock. Finally, Royal Bank Of Canada boosted their price objective on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.55.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.